Navigation Links
ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12
Date:9/6/2011

SAN DIEGO, Sept. 6, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Monday September 12, 2011 at 2:25 p.m. Eastern time, in the Metropolitan East Salon at the Waldorf=Astoria Hotel in New York.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on developing proprietary product candidates.  The Company's current lead product candidates are ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis, and ANX-514, a detergent-free reformulation of the blockbuster drug Taxotere®, which recently went off-patent.  The Company is evaluating its Exelbine program following the complete response letter it received from the FDA.  More information can be found on the Company's web site at www.adventrx.com.  


'/>"/>
SOURCE ADVENTRX Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ADVENTRX Provides Update on All Three Pipeline Products
2. ADVENTRX Reports Second Quarter 2011 Financial Results
3. ADVENTRX Pharmaceuticals to Present at the 31st Annual Canaccord Genuity Growth Conference on August 11
4. Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
5. ADVENTRX Reports First Quarter 2011 Financial Results
6. ADVENTRX Completes Acquisition of SynthRx
7. ADVENTRX Pharmaceuticals Provides Update on ANX-514
8. ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc.
9. ADVENTRX to Provide Update Regarding Pipeline Expansion Efforts
10. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIOCEO & Investor Conference on February 15
11. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Oregon and PUNE, India ... to a new report published by Allied Market Research, ... Global Opportunity Analysis and Industry Forecast, 2014-2022," the global ... by 2022, from $5,768 million in 2015, growing at ... chemical & gas sterilization segment dominated the market in ...
(Date:1/16/2017)... 16, 2017 Transparency Market Research states ... Devices Market  held a huge share of 43% in 2015. ... frontrunners in the overall market, grabbing the undivided attention of ... across geographies, and strong product portfolio is expected to keep ... ...
(Date:1/16/2017)... 16, 2017  Dovetail Genomics today announced the commercial ... service, which yields chromosome-scale genome assemblies. The service is ... workshop on Jan. 17 at the Plant & Animal ... . "We are thrilled to be ... our Dovetail Hi-C offering," said Todd Dickinson , ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... ... demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF SHOT Show ... Vegas, Booth #2809. The SHOT Show is the shooting, hunting and outdoor trade ...
(Date:1/16/2017)... Smithtown, New York (PRWEB) , ... January 16, ... ... group, SightMD today announced the addition of Victor Giamos, MD to ... Officer of SightMD and Managing Partner at North Shore Eye Care, a division ...
(Date:1/16/2017)... St. Louis, MO (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware ... is here , This year’s influenza shot seems to be having no effect ... public area, at least half of the people around are coughing, sneezing, or sniffling ...
(Date:1/16/2017)... ... 2017 , ... One thing common to all types of cancer is that ... well. The money spent screening for and treating cancer in the United States is ... cancer more than in any other country that has an advanced healthcare system, sometimes ...
(Date:1/15/2017)... ... January 15, 2017 , ... In this role, Courtney will be responsible ... the asthma & allergy friendly mark. This certification program was created by ASL and ... products to be more suitable for the 60+ million people living in the U.S. ...
Breaking Medicine News(10 mins):